Clinical Trials Browser

OTHER × tremelimumab × Plasma cell × Clear all

NCT02716805 2022-10-12

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

Phase 1 Terminated

6 enrolled 11 charts

Diabetes Mellitus, Insulin-Dependent, 12, Multiple Myeloma